343 related articles for article (PubMed ID: 10337430)
21. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
[TBL] [Abstract][Full Text] [Related]
22. Involvement of chymase in allergic conjunctivitis of guinea pigs.
Nabe T; Kijitani Y; Kitagawa Y; Sakano E; Ueno T; Fujii M; Nakao S; Sakai M; Takai S
Exp Eye Res; 2013 Aug; 113():74-9. PubMed ID: 23726880
[TBL] [Abstract][Full Text] [Related]
23. Topical Olopatadine in the Treatment of Allergic Conjunctivitis: A Systematic Review and Meta-analysis.
Kam KW; Chen LJ; Wat N; Young AL
Ocul Immunol Inflamm; 2017 Oct; 25(5):663-677. PubMed ID: 27192186
[TBL] [Abstract][Full Text] [Related]
24. A review of the use of olopatadine in allergic conjunctivitis.
McGill JI
Int Ophthalmol; 2004 May; 25(3):171-9. PubMed ID: 15847317
[TBL] [Abstract][Full Text] [Related]
25. Preclinical efficacy of emedastine, a potent, selective histamine H1 antagonist for topical ocular use.
Yanni JM; Stephens DJ; Parnell DW; Spellman JM
J Ocul Pharmacol; 1994; 10(4):665-75. PubMed ID: 7714410
[TBL] [Abstract][Full Text] [Related]
26. Overview of ocular allergy treatment.
Friedlaender M
Curr Allergy Asthma Rep; 2001 Jul; 1(4):375-9. PubMed ID: 11892061
[TBL] [Abstract][Full Text] [Related]
27. Role of histamine in allergic conjunctivitis.
Leonardi A
Acta Ophthalmol Scand Suppl; 2000; (230):18-21. PubMed ID: 11057344
[TBL] [Abstract][Full Text] [Related]
28. The central role of conjunctival mast cells in the pathogenesis of ocular allergy.
Leonardi A
Curr Allergy Asthma Rep; 2002 Jul; 2(4):325-31. PubMed ID: 12044269
[TBL] [Abstract][Full Text] [Related]
29. Interactions of olopatadine and selected antihistamines with model and natural membranes.
Brockman HL; Momsen MM; Knudtson JR; Miller ST; Graff G; Yanni JM
Ocul Immunol Inflamm; 2003 Dec; 11(4):247-68. PubMed ID: 14704897
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis.
Bielory L; Lien KW; Bigelsen S
Drugs; 2005; 65(2):215-28. PubMed ID: 15631542
[TBL] [Abstract][Full Text] [Related]
31. Levocabastine. An update of its pharmacology, clinical efficacy and tolerability in the topical treatment of allergic rhinitis and conjunctivitis.
Noble S; McTavish D
Drugs; 1995 Dec; 50(6):1032-49. PubMed ID: 8612470
[TBL] [Abstract][Full Text] [Related]
32. [Allergic conjunctivitis in children].
Zepeda Ortega B; Rosas Vargas MA; Ito Tsuchiya FM; del Río Navarro BE; Sienra Monge JJ
Rev Alerg Mex; 2007; 54(2):41-53. PubMed ID: 17542245
[TBL] [Abstract][Full Text] [Related]
33. Onset of action, effectiveness and tolerance of levocabastine and nedocromil in topical therapy of seasonal allergic rhinoconjunctivitis. The Deutsche Rhinitis-Studiengruppe.
Kremer B; Tündermann A; Goldschmidt O
Arzneimittelforschung; 1998 Sep; 48(9):924-30. PubMed ID: 9793620
[TBL] [Abstract][Full Text] [Related]
34. Levocabastine. A review of its pharmacological properties and therapeutic potential as a topical antihistamine in allergic rhinitis and conjunctivitis.
Dechant KL; Goa KL
Drugs; 1991 Feb; 41(2):202-24. PubMed ID: 1709851
[TBL] [Abstract][Full Text] [Related]
35. Evaluating the efficacy of epinastine ophthalmic solution using a conjunctivitis allergen challenge model in patients with birch pollen allergic conjunctivitis.
Tagawa Y; Namba K; Nakazono Y; Iwata D; Ishida S
Allergol Int; 2017 Apr; 66(2):338-343. PubMed ID: 27720602
[TBL] [Abstract][Full Text] [Related]
36. A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model.
Greiner JV; Udell IJ
Clin Ther; 2005 May; 27(5):568-77. PubMed ID: 15978305
[TBL] [Abstract][Full Text] [Related]
37. New trends in the treatment of allergic conjunctivitis.
Parys W; Blockhuys S; Janssens M
Doc Ophthalmol; 1992; 82(4):353-60. PubMed ID: 1363981
[TBL] [Abstract][Full Text] [Related]
38. Topical azelastine in perennial allergic conjunctivitis.
Canonica GW; Ciprandi G; Petzold U; Kolb C; Ellers-Lenz B; Hermann R
Curr Med Res Opin; 2003; 19(4):321-9. PubMed ID: 12841925
[TBL] [Abstract][Full Text] [Related]
39. [Pharmacological and clinical properties of levocabastine hydrochloride (eye drop and nasal spray), a selective H1 antagonist].
Akiyoshi M; Shigeoka T; Torii S; Maki E; Enomoto S; Takahashi H; Hirano F
Nihon Yakurigaku Zasshi; 2002 Mar; 119(3):175-84. PubMed ID: 11915520
[TBL] [Abstract][Full Text] [Related]
40. Immunomodulators for conjunctivitis.
Pacharn P; Vichyanond P
Curr Opin Allergy Clin Immunol; 2013 Oct; 13(5):550-7. PubMed ID: 23974685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
